1. 316 Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors. (September 2015) Authors: Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Coronado, C.; Juan, L.; Fernandez-Teruel, C.; Soto-Matos, A.; Stathis, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors. (September 2015) Authors: Garralda, E.; Stathis, A.; Drilon, A.; Boni, V.; Hyman, D.; Calvo, E.; Griguolo, G.; Makker, V.; Doger, B.; Canziani, L.; Varghese, A.M.; Jimenez, E.; Luque, J.; Soto-Matos, A.; Szyldergemajn, S.; Sessa, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 361 Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1-3 and 15-17 every 28 days to patients with advanced malignant solid tumors. (September 2015) Authors: Hidalgo, M.; Boni, V.; Tolcher, A.; Smith, L.; Cubillo, A.; Rasco, D.; Calvo, E.; Amaya, A.; Ordoñez, E.; Patnaik, A.; Cerda, S.; Coronado, C.; Fudio, S.; Miguel-Lillo, B.; Prados, R.; Ortega, O.; Soto-Matos, A.; Papadopoulos, K.P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗